Nanomicellar formulations for sustained drug delivery: strategies and underlying principles.
Micellar delivery systems smaller than 100 nm can be readily prepared. While micelles allow a great depth of tissue penetration for targeted drug delivery, they usually disintegrate rapidly in the body. Thus, sustained drug delivery from micellar nanocarriers is a challenge. This article summarizes various key strategies and underlying principles for sustained drug delivery using micellar nanocarriers. Comparisons are made with other competing delivery systems such as polymeric microparticles and nanoparticles. Amphiphilic molecules self-assemble in appropriate liquid media to form nanoscale micelles. Strategies for sustained release nanomicellar carriers include use of prodrugs, drug polymer conjugates, novel polymers with low critical micellar concentration or of a reverse thermoresponsive nature, reverse micelles, multi-layer micelles with layer by layer assembly, polymeric films capable of forming micelles in vivo and micelle coats on a solid support. These new micellar systems are promising for sustained drug delivery.
Trivedi
Ruchit
R
Department of Pharmaceutical Sciences, University of Colorado Denver, 12700 E 19th Avenue, C238-P15, Aurora, CO 80045, USA.
Kompella
Uday B
UB
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008823:Micelles; D049329:Nanostructures / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods*
D008823:Micelles
J Control Release. 2001 Jan 29;70(1-2):63-70
11166408
Macromol Biosci. 2009 May 13;9(5):515-24
19089867
J Control Release. 2006 May 1;112(1):57-63
16516326
Drug Deliv. 2001 Apr-Jun;8(2):99-106
11400869
BJU Int. 2009 Apr;103(7):978-86
19007363
Pharm Res. 2008 Jan;25(1):194-206
17912488
Pharmazie. 2008 Jun;63(6):446-52
18604988
Biomacromolecules. 2009 Jun 8;10(6):1532-9
19361215
Int J Pharm. 2009 Mar 18;369(1-2):170-5
19028556
Int J Cancer. 2009 Jun 1;124(11):2505-11
19189401
J Control Release. 2002 Feb 19;79(1-3):165-72
11853928
Colloids Surf B Biointerfaces. 2007 Apr 1;55(2):222-8
17254755
ACS Nano. 2008 Feb;2(2):386-92
19206641
Int J Pharm. 2009 May 21;373(1-2):100-6
19429294
J Control Release. 2000 Aug 10;68(2):167-74
10925125
Urology. 2003 Feb;61(2 Suppl 1):25-31
12667884
Macromol Biosci. 2008 Dec 8;8(12):1116-25
18663739
Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1192-201
12601049
J Biomed Mater Res A. 2007 May;81(2):326-33
17120218
Colloids Surf B Biointerfaces. 2008 Oct 1;66(1):26-33
18583109
Pharmacol Ther. 2006 Dec;112(3):630-48
16815554
Bioconjug Chem. 2001 Nov-Dec;12(6):917-23
11716682
J Control Release. 2008 Jul 2;129(1):33-40
18456363
J Invasive Cardiol. 2009 May;21(5):E77-80
19411730
Appl Environ Microbiol. 2006 Nov;72(11):7390-3
16980422
J Biomed Mater Res A. 2005 Dec 1;75(3):639-47
16110497
Angew Chem Int Ed Engl. 2008;47(30):5573-6
18567037
J Colloid Interface Sci. 2004 May 15;273(2):626-31
15082402
Biomacromolecules. 2009 Apr 13;10(4):732-41
19235932
J Control Release. 2009 Jun 19;136(3):187-95
19289148
J Biomed Mater Res B Appl Biomater. 2006 Apr;77(1):188-94
16245284
Bioconjug Chem. 2008 Nov 19;19(11):2231-8
18847230
Int J Antimicrob Agents. 2001 Sep;18(3):245-52
11673037
Int J Pharm. 2009 Mar 31;370(1-2):210-5
19114094
Biomaterials. 2009 May;30(13):2606-13
19162320
Biotechnol Annu Rev. 2001;7:87-129
11686050
Biomaterials. 2009 Jun;30(17):3100-9
19342093
Am J Vet Res. 2004 Jun;65(6):752-7
15198214
Cancer Res. 2003 Dec 15;63(24):8977-83
14695216
Macromol Biosci. 2009 May 13;9(5):456-63
19089869
Pharm Res. 2007 Oct;24(10):1944-53
17530389
Colloids Surf B Biointerfaces. 2007 Oct 15;60(1):117-24
17644325
Gene Ther. 2009 May;16(5):645-59
19194480
J Control Release. 2006 May 1;112(1):64-71
16507325
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3095-101
17048523
Acta Pharm. 2009 Jun;59(2):133-44
19564139
Pharm Res. 2007 Jan;24(1):1-16
17109211
J Control Release. 2001 Jun 15;73(2-3):137-72
11516494
J Biomed Mater Res A. 2008 Sep 15;86(4):914-25
18067189
J Clin Oncol. 2008 May 20;26(15):2526-31
18487569